Bright Minds Biosciences Stock
Bright Minds Biosciences Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Ian McDonald
- Employees
- 26
- Market cap
- $506 M
- IPO
- 22/03/2021
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed…
Bright Minds Biosciences stock: price history
1D
-5.4%
1W
-5.1%
1M
-13.2%
6M
-42.9%
YTD
-34.3%
1Y
-22.7%
2Y
+78.1%
5Y
+38.1%
10Y
–
Next earnings date
Next earnings date
22/12/2026 (in 66 days)
Volatility around earnings
~42% weaker price swings than usual
Ask the agents about Bright Minds Biosciences
Analyst assessment of Bright Minds Biosciences
PRICE TARGET LOW
US$145.00
CONSENSUS
US$171.67
MEDIAN
US$150.00
PRICE TARGET HIGH
US$220.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 19/08/2026
Bright Minds Biosciences stock metrics
P/E
-25.18
P/B
2.33
EV/EBITDA
-10.38
RETURN ON EQUITY
-0.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
67.8%
FLOAT SHARES
6,691,582
AVG. DAILY VOLUME (30D)
126,038
Insider transactions (SEC)
Cormorant Asset Management, LP
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -5.4%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Bright Minds Biosciences stock
What does Bright Minds Biosciences do?
Bright Minds Biosciences Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Ian McDonald, the company employs around 26 people.
The IPO was on 22/03/2021; the stock trades on NASDAQ under the ticker DRUG.
What do analysts say about Bright Minds Biosciences stock?
4 analysts rate the stock, the consensus is Buy (as of 19/08/2026).
The average price target is US$171.67, ranging from US$145.00 to US$220.00, with a median of US$150.00.
This is an external assessment, not a statement by Market Jury.
When does Bright Minds Biosciences report next?
The next earnings date is 22/12/2026.
Around past earnings, price swings were roughly -42% stronger than usual.
Does Bright Minds Biosciences pay a dividend?
No, Bright Minds Biosciences currently does not pay a dividend.
Which stocks are comparable to Bright Minds Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Bright Minds Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Bright Minds Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.